4.55
-0.1(-2.15%)
Currency In USD
| Previous Close | 4.65 |
| Open | 4.69 |
| Day High | 4.8 |
| Day Low | 4.45 |
| 52-Week High | 6.02 |
| 52-Week Low | 1.05 |
| Volume | 2.08M |
| Average Volume | 3.03M |
| Market Cap | 1.09B |
| PE | -13.79 |
| EPS | -0.33 |
| Moving Average 50 Days | 5.07 |
| Moving Average 200 Days | 3.71 |
| Change | -0.1 |
If you invested $1000 in Taysha Gene Therapies, Inc. (TSHA) since IPO date, it would be worth $189.11 as of February 15, 2026 at a share price of $4.55. Whereas If you bought $1000 worth of Taysha Gene Therapies, Inc. (TSHA) shares 5 years ago, it would be worth $155.72 as of February 15, 2026 at a share price of $4.55.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
First patient dosed in REVEAL pivotal trial evaluating TSHA-102 (N=15, aged 6 to <22 years) in Q4 2025, with enrollment advancing across multiple sites Reached written alignment with FDA on inclusion of ≥3 months of safety data from ASPIRE trial eval
Taysha Gene Therapies to Release Third Quarter 2025 Financial Results and Host Conference Call and Webcast on November 4
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
DALLAS, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic disease
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
GlobeNewswire Inc.
Oct 16, 2025 8:01 PM GMT
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and optionality TSHA-102 has demonstrated